News
A study led by Harvard Medical School, explored the reason that causes the rise of aortic aneurysms, thus offering vital ...
Indian firms have secured rights to produce Lenacapavir, a twice-yearly HIV injection, making treatment easier and affordable. This new drug promises better adherence and wider access, especially in ...
Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug
Indian firms have secured rights to produce Lenacapavir, a twice-yearly HIV injection, making treatment easier and affordable ...
2hon MSN
The FDA's approval of lenacapavir, a highly effective HIV prevention drug, sparks debate in India due to its high cost of ₹24 ...
HIV targets the white blood cells and weakens the immune system. This would make the person prone to diseases like ...
The US FDA has approved lenacapavir, the first twice-yearly injection for HIV prevention, which provides near-complete ...
Sarah Kasadha, the Deputy Resident District Commissioner (RDC), criticized the growing trend as a sign of declining ...
Speaking at a two-day training retreat at the Source of the Nile Hotel, Dr. Egessa Simplicious, Public Relations Officer at ...
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results